Evidence map›Paper›PMID 36711510›Full record

ArticlebioRxiv : the preprint server for biology2023

Antimicrobial mitochondrial reactive oxygen species induction by lung epithelial metabolic reprogramming.

Yongxing Wang, Vikram V Kulkarni, Jezreel Pantaleón García, Miguel M Leiva-Juárez, David L Goldblatt, Fahad Gulraiz, Jichao Chen, Sri Ramya Donepudi, Philip L Lorenzi, Hao Wang and 3 more

Open access · greenAbstract readPreprint
In one paragraph

Article in bioRxiv : the preprint server for biology, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed, 0 citations in OpenAlex.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

13 authors at 1 institution in 1 country.

Yongxing WangDepartment of Pulmonary Medicine, University of Texas MD Anderson Cancer Center, Houston, Texas, USA.
Vikram V KulkarniDepartment of Pulmonary Medicine, University of Texas MD Anderson Cancer Center, Houston, Texas, USA.
Jezreel Pantaleón GarcíaDepartment of Pulmonary Medicine, University of Texas MD Anderson Cancer Center, Houston, Texas, USA.
Miguel M Leiva-JuárezDepartment of Pulmonary Medicine, University of Texas MD Anderson Cancer Center, Houston, Texas, USA.
David L GoldblattDepartment of Pulmonary Medicine, University of Texas MD Anderson Cancer Center, Houston, Texas, USA.
Fahad GulraizDepartment of Pulmonary Medicine, University of Texas MD Anderson Cancer Center, Houston, Texas, USA.
Jichao ChenDepartment of Pulmonary Medicine, University of Texas MD Anderson Cancer Center, Houston, Texas, USA.
Sri Ramya DonepudiUniversity of Texas MD Anderson Cancer Center UTHealth Graduate School of Biomedical Sciences, Houston, Texas, USA.
Philip L LorenziUniversity of Texas MD Anderson Cancer Center UTHealth Graduate School of Biomedical Sciences, Houston, Texas, USA.
Hao WangDepartment of Bioinformatics and Computational Biology, University of Texas MD Anderson Cancer Center, Houston, Texas, USA.
Lee-Jun WongDepartment of Bioinformatics and Computational Biology, University of Texas MD Anderson Cancer Center, Houston, Texas, USA.
Michael J TuvimDepartment of Pulmonary Medicine, University of Texas MD Anderson Cancer Center, Houston, Texas, USA.
Scott E EvansDepartment of Pulmonary Medicine, University of Texas MD Anderson Cancer Center, Houston, Texas, USA.
The University of Texas MD Anderson Cancer Center · US

Funding

Tumor Evolution and Metastasis ProgramP30CA016672 · NCI · UNIVERSITY OF TX MD ANDERSON CAN CTR · PI DIANE BODURKA · 1985 to 2026
$290.8M
Inducible epithelial resistance: a program investigating mechanisms to protect against acute and chronic complications of pneumoniaR35HL144805 · NHLBI · UNIVERSITY OF TX MD ANDERSON CAN CTR · PI EVANS, SCOTT E. · 2019 to 2025
$6.2M
Role of AT1 cells in perinatal lung maturationR01HL130129 · NHLBI · UNIVERSITY OF TX MD ANDERSON CAN CTR · PI CHEN, JICHAO · 2016 to 2023
$4.1M
Transcriptional and epigenetic basis of lung epithelial cell fateR01HL153511 · NHLBI · UNIVERSITY OF TX MD ANDERSON CAN CTR · PI CHEN, JICHAO · 2020 to 2023
$2.5M
Inducible epithelial antiviral resistance to prevent asthmaDP2HL123229 · NHLBI · UNIVERSITY OF TX MD ANDERSON CAN CTR · PI EVANS, SCOTT E. · 2013 to 2013
$2.4M
Epithelial mechanisms of inducible resistance to AML-associated pneumoniaR01HL117976 · NHLBI · UNIVERSITY OF TX MD ANDERSON CAN CTR · PI EVANS, SCOTT E. · 2014 to 2018
$2.0M
Orbitrap Elite High-Resolution Mass Spectrometer for Proteomics and MetabolomicsS10OD012304 · OD · UNIVERSITY OF TX MD ANDERSON CAN CTR · PI HAWKE, DAVID H · 2013 to 2013
$877k
NCI NIH HHS P30 CA016672NHLBI NIH HHS DP2 HL123229NHLBI NIH HHS R01 HL117976NHLBI NIH HHS R01 HL130129NHLBI NIH HHS R01 HL153511NHLBI NIH HHS R35 HL144805NIH HHS S10 OD012304
6 · The paper itself

Abstract

Pneumonia is a worldwide threat, making discovery of novel means to combat lower respiratory tract infections an urgent need. We have previously shown that manipulating the lungs' intrinsic host defenses by therapeutic delivery of a unique dyad of pathogen-associated molecular patterns protects mice against pneumonia in a reactive oxygen species (ROS)-dependent manner. Here we show that antimicrobial ROS are induced from lung epithelial cells by interactions of CpG oligodeoxynucleotides (ODNs) with mitochondrial voltage-dependent anion channel 1 (VDAC1) without dependence on Toll-like receptor 9 (TLR9). The ODN-VDAC1 interaction alters cellular ATP/ADP/AMP localization, increases delivery of electrons to the electron transport chain (ETC), enhances mitochondrial membrane potential (Δ Author Summary: Pneumonia is a major cause of death worldwide. Increasing antibiotic resistance and expanding immunocompromised populations continue to enhance the clinical urgency to find new strategies to prevent and treat pneumonia. We have identified a novel inhaled therapeutic that stimulates lung epithelial defenses to protect mice against pneumonia in a manner that depends on production of reactive oxygen species (ROS). Here, we report that the induction of protective ROS from lung epithelial mitochondria occurs following the interaction of one component of the treatment, an oligodeoxynucleotide, with the mitochondrial voltage-dependent anion channel 1. This interaction alters energy transfer between the mitochondria and the cytosol, resulting in metabolic reprogramming that drives more electrons into the electron transport chain, then causes electrons to leak from the electron transport chain to form protective ROS. While antioxidant therapies are endorsed in many other disease states, we present here an example of therapeutic induction of ROS that is associated with broad protection against pneumonia without reliance on administration of antibiotics.

Identifiers

PMID36711510
PMCPMC9882263
OpenAlexW4317653962

What Socratic holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.